Completed PHASE2 INTERVENTIONAL 1-arm NCT00434109

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Islet Cell Tumor Neuroendocrine Tumor

Interventions Hepatic Artery Embolizations Sunitinib malate

Updated 5 times since 2017 Last updated: Sep 7, 2012 Started: Nov 30, 2006 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Islet Cell Tumor and Neuroendocrine Tumor and is currently completed. H. Lee Moffitt Cancer Center and Research Institute leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States